秘鲁库斯科学龄前及学龄儿童肝片形吸虫感染三氯苯达唑治疗失败研究
本研究为秘鲁高地慢性片形吸虫病儿童的回顾性队列研究,评估三氯苯达唑疗效。146名儿童接受直接观察治疗(>1剂10 mg/kg),首次治疗后55%获寄生虫学治愈,治愈率随治疗次数下降(第二次38%、第三次30%、第四次23%),17名(11.6%)4次治疗未愈。基线虫卵计数较高和较低社会经济地位与治疗失败相关。
要点
- 首次三氯苯达唑治疗后仅55%患儿获寄生虫学治愈。
- 重复治疗治愈率递减:第二次38%、第三次30%、第四次23%。
- 17名(11.6%)患儿经4次治疗仍未治愈。
核心结论
- 在疾病流行社区,三氯苯达唑疗效下降威胁控制工作,亟需开展耐药性及新药研究。
研究设计与样本
- 回顾性队列研究,纳入146名秘鲁高地慢性片形吸虫病儿童,53%为女性,平均年龄10.4±3.1岁。
- 患儿接受直接观察下三氯苯达唑治疗(>1剂10 mg/kg),每次治疗后1-4个月通过粪便镜检评估寄生虫学治愈。
主要发现
- 首次治疗后55%的儿童达到寄生虫学治愈。
- 治愈率随治疗次数下降:第二次38%、第三次30%、第四次23%。
- 17名儿童(11.6%)在4次治疗后仍未治愈。
- 较高的基线虫卵计数和较低的社会经济地位与三氯苯达唑治疗失败相关。
临床怎么用
- 在流行区对慢性片形吸虫病患儿应评估三氯苯达唑疗效,重复治疗需注意治愈率可能下降。
- 对基线虫卵计数高或社会经济地位低的患儿应加强随访和疗效监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted a retrospective cohort study of children who had chronic fascioliasis in the highlands of Peru to determine triclabendazole treatment efficacy. Children passing Fasciola eggs in stool were offered directly observed triclabendazole treatment (>1 doses of 10 mg/kg). Parasitologic cure was evaluated by using microscopy of stool 1-4 months after each treatment. A total of 146 children who had chronic fascioliasis participated in the study; 53% were female, and the mean ± SD age was 10.4 ± 3.1 years. After the first treatment, 55% of the children achieved parasitologic cure. Cure rates decreased after the second (38%), third (30%), and fourth (23%) treatments; 17 children (11.6%) did not achieve cure after 4 treatments. Higher baseline egg counts and lower socioeconomic status were associated with triclabendazole treatment failure. Decreased triclabendazole efficacy in disease-endemic communities threatens control efforts. Further research on triclabendazole resistance and new drugs to overcome it are urgently needed.
引用
- Morales ML, Tanabe MB, White AC, et al. Triclabendazole Treatment Failure for Fasciola hepatica Infection among Preschool and School-Age Children, Cusco, Peru1. Emerg Infect Dis. 2021. PMID: 34152949. doi:10.3201/eid2707.203900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。